Key result
Gerotherapeutics show potential to boost molecular resilience and transform cardiovascular care in older adults.
Geroscience and gerotherapeutics offer a novel paradigm to address age-related molecular damage, potentially transforming the management of cardiovascular disease in older adults with multimorbidity and frailty.
Geroscience posits that cardiovascular disease (CVD) and other chronic diseases result from progressive erosion of the effectiveness of homeostatic mechanisms that oppose age-related accumulation of molecular damage. This hypothetical common root to chronic diseases explains why patients with CVD are often affected by multimorbidity and frailty and why older age negatively affects CVD prognosis and treatment response. Gerotherapeutics enhance resilience mechanisms that counter age-related molecular damage to prevent chronic diseases, frailty, and disability, thereby extending healthspan. Here, we describe the main resilience mechanisms of mammalian aging, with a focus on how they can affect CVD pathophysiology. We next present novel gerotherapeutic approaches, some of which are already used in management of CVD, and explore their potential to transform care and management of CVD. The geroscience paradigm is gaining traction broadly in medical specialties, with potential to mitigate premature aging, reduce health care disparities, and improve population healthspan.
No takes yet. Share an insight, caveat, or question.
Forman et al. (2023) conducted a review in Cardiovascular disease in older adults. Gerotherapeutics was evaluated. Gerotherapeutics have the potential to enhance resilience mechanisms against age-related molecular damage, transforming the care and management of cardiovascular disease in older adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: